Galapagos and LEO Pharma Collaborate on Antibacterial Research
Subset of Galapagos' collection used for LEO pharma's antibacterial research program.!--h2>
BioFocus, Galapagos' service division, will use a subset of its natural compound collection for high-throughput screening, hit verification, and profiling of selected compounds for LEO Pharma's antibacterial research program. This collaboration marks Galapagos' first for its natural compound collection.
Galapagos stands to receive up to EUR 400,000 in project fees and up to EUR 3 million in milestone payments. The company may also receive royalties on sales of commercial products resulting from the collaboration.
BioFocus says its natural compound collections are based on bacterial and fungal sources, offering characteristics differentiating these from synthetic chemistry collections, including high chemical and functional diversity, potent pharmacological activities over a broad range of biological targets, and desirable physicochemical properties.